Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia

MicroRNAs (miRNAs) are small (19-22-nt) single-stranded noncoding RNA molecules whose deregulation of expression can contribute to human disease including the multistep processes of carcinogenesis in human. Circulating miRNAs are emerging biomarkers in many diseases and cancers such as type 2 diabet...

Full description

Saved in:
Bibliographic Details
Published in:Journal of translational medicine 2013-02, Vol.11 (1), p.31-31, Article 31
Main Authors: Fayyad-Kazan, Hussein, Bitar, Nizar, Najar, Mehdi, Lewalle, Philippe, Fayyad-Kazan, Mohammad, Badran, Rabih, Hamade, Eva, Daher, Ahmad, Hussein, Nader, ElDirani, Rim, Berri, Fadwa, Vanhamme, Luc, Burny, Arsène, Martiat, Philippe, Rouas, Redouane, Badran, Bassam
Format: Article
Language:English
Subjects:
Acute myeloblastic leukemia
Acute myeloid leukemia
AML
Area Under Curve
Biomarker
biomarkers
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
Bone marrow
Carcinogenesis
Case-Control Studies
Colorectal cancer
Diabetes mellitus
Gastric cancer
Gene Expression Profiling
Humans
Leukemia
Leukemia, Myeloid, Acute - blood
Leukemia, Myeloid, Acute - genetics
Lung cancer
Lung diseases
Medical research
Micro-RNA
MicroRNAs - blood
MicroRNAs - genetics
miRNA
Oligonucleotide Array Sequence Analysis
Plasma
Polymerase chain reaction
Real-Time Polymerase Chain Reaction
Remission
RNA
ROC Curve
Translation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MicroRNAs (miRNAs) are small (19-22-nt) single-stranded noncoding RNA molecules whose deregulation of expression can contribute to human disease including the multistep processes of carcinogenesis in human. Circulating miRNAs are emerging biomarkers in many diseases and cancers such as type 2 diabetes, pulmonary disease, colorectal cancer, and gastric cancer among others; however, defining a plasma miRNA signature in acute myeloblastic leukemia (AML) that could serve as a biomarker for diagnosis or in the follow-up has not been done yet. TaqMan miRNA microarray was performed to identify deregulated miRNAs in the plasma of AML patients. Quantitative real-time RT-PCR was used to validate the results. Receiver-operator characteristic (ROC) curve analysis was conducted to evaluate the diagnostic accuracy of the highly and significantly identified deregulated miRNA(s) as potential candidate biomarker(s). The plasma expression level of let-7d, miR-150, miR-339, and miR-342 was down-regulated whilst that of let-7b, and miR-523 was up-regulated in the AML group at diagnosis compared to healthy controls. ROC curve analyses revealed an AUC (the areas under the ROC curve) of 0.835 (95% CI: 0.7119- 0.9581; P
ISSN:1479-5876
1479-5876
DOI:10.1186/1479-5876-11-31